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Abstract 
AIM: The goals of this paper are: to report the incidence of AML in elderly, to describe cytogenetic characteristics 
of this population, to observe rare and novel cytogenetic abnormalities and lastly, to compare our finding with that 
previously reported in the literature. 
METHODS: We conducted a retrospective analysis of 283 patients with acute myeloid leukaemia (AML) treated in 
our unit, we will report the incidence of AML in elderly, describe cytogenetic characteristics of this population, 
observe rare and novel cytogenetic abnormalities and compare our finding with that previously reported in the 
literature.  
RESULTS: Among the 283 patients, 157 (54.4%) patients performed the karyotype, the cytogenetic analysis 
failed in 17 cases (11%). Prognostic group distribution was found to be favorable in 8 patients (6%) with 6 cases 
of t (8; 21) and 2 cases of inv (16), intermediate group in 94 patients (67%), including 58 cases (41,5%) with a 
normal karyotype, and an unfavorable group in 38 patients (27%) including complex karyotype (15%), -5 or del 5q 
(3%), -7 or del 7q (3.5%), t (9; 22) (2%). Some rare anomalies were observed.  
CONCLUSION: However, the occurrence of a complex karyotype was more frequent than younger patients. In 
our unit, elderly benefit from supportive care, our study shows that it is a heterogeneous group and our treatment 
approach have to change especially for the patient from favourable risk group who can benefit from intensive 
chemotherapy. We have to improve our diagnosis with including molecular genetics that provides a documented 
substrate for a thoughtfully considered treatment plan. 
 
 
 
 
 
 
 
 
 
Introduction 
 
AML is an aggressive haematological 
malignancy, it’s a rare disease, the incidence of AML 
increase with age, the median age at diagnosis is 67 
years [1], the management of those patients is 
particularly difficult, both the nature of disease and the 
health of patient change with age, the take care of this 
fragile population is a veritable challenge for 
practician.  
The cytogenetic profiles of elderly patients 
with AML are different from that of younger patients 
with more chromosomal abnormalities. The outcome 
in older adults is poor, high rates of good response 
translate into a 2-years survival of only about 15% to 
20% [2], it’s can be explained by a significant 
individual heterogeneity for those patients. Comorbid 
conditions, performance status, and decreased 
immune competence of elderly patients compromised 
the management of AML, and curative therapy as 
bone marrow transplantation cannot be proposed for 
those patients. On the other hand, AML in the elderly 
is not the same that younger people, a distinct gene 
expression profile noted for older compared with 
younger patients [3], [4]. 
 A little is known about the cytogenetic profile 
of AML in Morocco, few studies are done, and no 
studies for elderly patients with AML are performed. In 
this article, we will try to describe the cytogenetic 
characteristics of patients having de novo acute 
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myeloid leukaemia AML aged more than 60 years 
treated in our unit from 2004 to 2016.  
The goals of this paper are: to report the 
incidence of AML in elderly, to describe cytogenetic 
characteristics of this population, to observe rare and 
novel cytogenetic abnormalities and lastly, to compare 
our finding with that previously reported in the 
literature. 
 
 
Patients and methods 
 
The patients were identified by review of 
medical records at haematology and pediatric 
oncology centre of Casablanca, in Morocco during the 
period from January 2004 to July 2016. Informed 
consent was obtained from all individual participants 
included in the study. The patients had to have more 
than 60 years and should be followed for AML. Also, 
patients had to have a cytogenetic analysis at 
diagnosis. All samples were sent to a single reference 
laboratory who worked in collaboration with the 
university hospital.  
Diagnosis of AML was confirmed by bone 
marrow aspiration and stained with May-Grunwald-
Giemsa, and myeloperoxidase (MPO). The marrow 
blast count of 20% was required, and AML was 
classified into eight subtypes M0 to M7 according to 
the French American British (FAB) classification [5], 
[6].
 
Previously, the immunophenotyping was done 
in case of AML with minimal differentiation (AML-M0), 
acute megakaryoblastic leukaemia (AML-M7), 
erythroblastic leukaemia (AML-M6) and acute 
leukaemia of ambiguous lineage. To improve our 
diagnosis criteria, immunophenotyping has been done 
systematically for all young patients since 2011, for 
the elderly, few of patients benefited from 
immunophenotyping,  
Cytogenetic analysis was done at diagnosis 
according to standard techniques with RHG banding. 
The bone marrow cells were cultured for 24 to 48 
hours. Twenty cells were analysed, although 
examination of lower numbers of metaphases was 
also acceptable if an abnormal clone was detected. 
An abnormality was considered clonal when at least 
two metaphases had the same aberration in case of a 
structural abnormality or an extra chromosome. If 
there was monosomy, it had to be present in at least 
three metaphases. All the samples were sent at the 
time of diagnosis, to a single reference laboratory who 
worked in collaboration with the university hospital.  
Chromosome identification and classification 
of chromosomal abnormalities were made according 
to the International System for Human Cytogenetic 
Nomenclature 2013 (ISCN) [7]. The cytogenetic 
findings were classified into three prognostic risk 
categories: favourable, intermediate and adverse, 
according to the classification proposed by Mrozek in 
2006 [8]. The favorable group included patients with t 
(8; 21)(q22; q22), t (15; 17)(q24; q21) and inv (16) 
(p13·1q22)/t(16; 16)(p13·1; q22), whether alone or in 
combination with other abnormalities. The 
intermediate group included patients with normal 
karyotype and other aberrations excluded in the 
favourable or adverse group. The adverse one 
included those with complex karyotype defined with 3 
or more abnormalities, inv (3) (q21q26)/t (3; 3) (q21; 
q26), t (6; 9) (p23; q34), t (6; 11) (q27; q23), t (11; 19) 
(q23; p13.1), del (5q) and monosomies 5 and 7. 
Cytogenetic abnormalities such as t(8;21), 
t(15;17), inv(16)/t(16;16), 11q23,+8, t(9;11), -5/del(5q) 
and -7/del(7q) were further evaluated as sole or in 
combination with other anomalies. For the t(8;21) the 
characteristics and associated abnormalities were 
detailed. 
To investigate the frequency of monosomal 
karyotype defined by the presence of at least 2 
autosomal monosomies or single autosomal 
monosomy associated with at least one structural 
abnormality, we studied the distribution of autosomal 
chromosomal monosomies among patients with 
cytogenetic abnormalities other than core-binding 
factor. 
Rare and novel abnormalities were also 
detailed. The research was done in the Atlas of 
Genetics and Cytogenetics in Oncology and 
Hematology [9] and Pubmed. All statistical analyses 
were evaluated using SPSS 16·0 software.  
 
 
Results 
 
From January 2004 to July 2016, 1483 
patients aged more than 19 years old, with the novo 
AML were followed in our department. One thousand 
and two hundred (80%) were aged between 20 and 
60 years old and 283 (20%) more than sixty years old. 
The total number of patients with de novo AML having 
more sixty than ears old entered the hospital per year 
varied between 12 patients on 2006 and 31 patients 
on 2011 with a median of 21 new patients per year. 
On the 283 patients, 150 (53%) were male, and 133 
(47%) were female; the sex-ratio was at 1:12. The 
median age was 69 years (61-99) old and distribution 
of patients’ ages per decade shows some difference 
of frequency: 151 (53.35%) patients were aged 
between 60 and 69 years, 100 (35.5%) between 70 
and 79 years, 32 (11.3%) had more than 80 years old. 
Immunophenotyping was performed in 46% of cases. 
AML-M2 was the most frequent subtype with 157 
(54.4%) patients. Patient’s characteristics are showed 
in Table 1. 
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Table 1: characterisation of clinical, biological and 
immunologic presentation of AML, by age (WBC: white blood 
cell; FAB: French-American-British) 
 60-69 years 70-79 years Older than 80 years 
No patients 151 100 32 
Novo  151 93 32 
Myélodysplasie. No 0 3 0 
Sex. Male No (%) 76 55 11 
Laboratory values, median (range) element/mm3 
WBC count 
29953 
(1000-184300) 
77330 
450-347000 
22278 
1100-229300 
FAB classification, No (%) 
M1 41 (27.15) 21 5 
M2 43 (28.48) 35 5 
M3 4 (2.65) 0 0 
M4 9 (5.96) 7 2 
M5 2 (1.32) 4 3 
M6 5 (3.31) 2 2 
M7 0 2 0 
M0 9 (5.96) 5 1 
Unknown 38 (25.16) 24 14 
 
Among the 283 patients, 157 (54.4%) patients 
performed the karyotype, the cytogenetic analysis 
failed in 17 cases (11%). The frequency of the most 
cytogenetic abnormalities detected at diagnosis 
among 157 cases of AML arising in older adults with 
cytogenetic study and their associated clinical, 
biologic and immunologic features are presented in 
table 2. Clonal abnormalities were observed in 82 
(58.5%) of the 157 patients. 
Prognostic group distribution was found to be 
favorable in 8 patients (6%) with 6 cases of t(8; 21) 
and 2 cases of inv (16), intermediate group in 94 
patients (67%), including 58 cases (41.5%) with a 
normal karyotype, and an unfavorable group in 38 
patients (27%) including complex karyotype (15%), -5 
or del 5q (9%), -7 or del 7q (5%), t(9,22) (2%). In our 
analyze we found some rare anomalies, like 
t(6,12)(q12; p12) ,+3, +7, +16, -21, and t (5.16). 
Table 2: Frequency and percentage of cytogenetic 
abnormalities (Percentage do not add to 100 because patients 
with more than one abnormality are counted more than once) 
 
Abnormality 
All patients 
(no:140) 
No 
60-69 years 70-79 years 
Older than 80 
years 
Normal 58 40 11 7 
complexe 21 17 4 0 
T(8,21) 6 6 0 0 
Inv(16) 2 2 0 0 
-5 /del(5q) 14 11 3 0 
-7 /del (7q) 8 7 1 0 
11q23 5 2 1 2 
T(9,22) 3 2 1 0 
Trisomy: 
+8 
+21 
+7 
+19 
+16 
+18 
+13 
+3 
24 
 
6 
3 
2 
0 
0 
1 
1 
0 
 
5 
0 
1 
1 
1 
0 
1 
1 
 
0 
0 
1 
0 
0 
0 
0 
0 
Monosomy 
-8 
-21 
-Y 
-X 
5 
 
 
 
0 
1 
0 
1 
 
2 
0 
1 
0 
 
0 
0 
0 
0 
Other 
abnormalities 
11 6 5 0 
Other abnormalities: del 12q ,del 20q, del 9q, del 8q, t(7,11)(p15 ;p15), t(9,11)(q23 ;q23), t(5,16)(q33,q22), t(3,5)(q26;q34),t(13,13)(q10 
;p10),t(13,14)(p11 ;q11), t(6,12)(q12 ;p12) 
However, the occurrence of a complex 
karyotype was more frequent than younger patients. 
t(8; 21) and t(15; 17) were seen less than younger 
patients. No significant variation in frequency of 
particular abnormalities across the age range was 
noted. Frequency and percentage of cytogenetic 
abnormalities among cases are shown in Table 2. 
In the favourable risk group t(8,21) was 
detected in 6 cases and it was accompanied by 
additional changes in 5 cases, the inversion of 
chromosome 6, it was found in 2 cases, it was 
presented as a sole abnormality. For the intermediate 
risk group, the majority of cases classified within the 
intermediate risk group had a normal karyotype 
(41.5%), the abnormalities that were detected were 
represented by trisomy 8 which was sole in 9 cases, 
and associated with trisomy 10 and trisomy 12 in one 
case. Trisomy 21 was observed in 3 cases, del 11q23 
was noted in 4 cases as a sole abnormalities, and 
associated with other changes in 1 case. Trisomy 7, 
trisomy 13 and trisomy 3 were found in 4, 2, and 
2cases respectively. Many single aberrations were 
detected like trisomy 18, trisomy 19, del 12q, del 9q, 
del 20q, del17q, monosomy 8, monosomy 20, loss of 
chromosome X and loss of chromosome Y. 
Overall, 38 of 157 cases were assigned to the 
unfavourable risk group, in 15%, this was based on 
the presence of complex karyotype, monosomy 5/del5 
was found in 12 cases sole, and in combination in 2 
cases, monosomy 7/del 7 was sole in 6 cases, and 
combined in 3 cases. 
Some new and rare abnormalities were noted 
like trisomy 3, trisomy 7, trisomy 16, monosomy 21. 
t(3,5)(q26;q34) as a sole anomaly was described in 68 
years old patient; we also found t(5,16)(q23,q22) in 61 
years old man. t(6,12) (q12;p12) was isolated in 
patient having 61 years old, other rare abnormalities 
were detected as t(13,14) (p11;q11), t(13,13) 
(q10;p10). 
 To further characterise the cytogenetic 
features of ML in older adults, we summarise the 
frequency of additional changes occurring in 
combination with primary chromosomal aberrations in 
Table 3. 
Table 3: The frequency of additional changes occurring in 
combination with primary chromosomal aberrations 
 Cytogenetic abnormalities 
 
To
tal 
T(8,
21) 
Inv(
16) 
-
7/d
el7 
-
5/d
el5 
11
q2
3 
monos
omies 
+
8 
+
2
1 
Other 
abnorm
alities 
Total   6 2 8 14 5     
Alone   1 2 4 2 4     
T(8,21)     1      
Inv(16)           
-7/del7     1      
-5/del5  1  1       
11q23     1      
Comple
xe 
   2 5 1     
+8  1         
+21           
-Y  1         
-X  1         
Other 
abnorm
alities 
 1   4      
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Discussion 
 
Acute myeloid leukaemia is a rare disease 
occurring in adults older than 55 years of age. It’s 
affecting annually 3-4 persons per 100000 individuals 
[10]. The median age of patients with AML is around 
70 years. AML is an aggressive haematological 
malignancy, with extremely poor prognosis with 
overall survival (OS) of less than 20% at 5 years [2]. 
The diagnosis of AML depends primarily on 
detection of leukemic blasts of myeloid lineage (more 
than 20%) in the bone marrow. The World Health 
Organization classifies AML into 4 major categories 
(each with 2 or more subtypes) using morphologic, 
immunophenotypic, genetic and clinical features. The 
main categories are (1) AML with recurrent genetic 
abnormalities, (2) AML with myélodysplasie-related 
features, (3) therapy-related AML and MDS, and (4) 
AML not otherwise specified. Genetic and molecular 
abnormalities highlight the heterogeneity of AML and 
identify subsets associated with better or worse 
prognosis. 
In Morocco, cytogenetic analysis was done 
systematically since 2004 for all young patients, but 
not all elderly patients benefited from the assessment 
at diagnosis. The number of patients how had 
cytogenetic and immunophenotyping analysis 
decrease with increasing ages.  
The cut-off of 60 years old is arbitrarily used 
to define “older” patients; it is unknown if with this age 
limit we can discriminate patients subgroups with 
different outcomes. In our unit, for adult patients with 
AML, treatment is proposed only for young patients, 
they are treated by a uniform protocol called AML-MA 
03 which included two inductions (7 + 3), two 
consolidations and a maintenance treatment without 
any stratification, this protocol was proposed from 
2003 to 2010. On 2011 another protocol, AML-MA 11 
was developed with two risk groups stratification 
based on the age (more or less than thirty years old) 
and cytogenetic finding as favourable, core binding 
factor (CBF) leukaemias with t(8;21) or 
inv(16)/t(16;16) versus all the others groups, the 
favourable group was receiving intensive 
chemotherapy involving cytarabine at a range of 
doses. Patients with acute promyelocytic leukaemia 
were treated by the APL-2004 protocol.  
Age was considered from many years one of 
the factors prognostic; it’s associated with poor 
outcome. Because the worst survival in AML elderly 
patients, the lack of resources and beds availability, 
we concentrate all our efforts to treat patients aged 
between 20 and sixty years old by improving the 
diagnosis, risk stratification and supportive care. 
Patients aged more than sixty years old receive 
systematically palliative care, we propose a low dose 
of aracytine, hypomethylating agents, and best 
supportive care with oral cytostatic drugs like 
hydroxyurea. Patients also benefited from 
transfusions, antibiotics and analgesics.  
In our study we found 283 patients aged more 
than 60 years old, with 53% of them aged between 60 
and 69 years. 
 Some factors are implicated in the adverse 
outcome of elderly in comparison with younger 
individuals. In this age group, AML has a particularly 
dismal outcome with less than 5% of the patients 
being alive 5 years after the diagnosis, as compared 
to 40% in the young [11], [12]. Advanced age is often 
accompanied by frailty and comorbidities [13], with 
poorer tolerance of combination chemotherapy 
regimens leading to the use of less intensive 
treatment protocols. Come of AML in the elderly; it is 
necessary to distinguish subgroups of patients with 
the paramount curable disease, who can receive 
treatment and those with incurable disease who can 
benefit from supportive care [14]. 
Age is not the unique factor of poor outcome; 
physical condition is very important; it can vary 
considerably among older people of the same age. 
Polypharmacy also constitutes an important 
prognostic factor [15]. Furthermore, poor prognosis in 
this group is associated with increased frequency of 
adverse cytogenetic features. Higher frequencies of 
adverse cytogenetics and unfavourable molecular 
aberrations are more common among the ageing 
populations. Distinct gene expression profiles noted 
for older compared with younger patients explain the 
poor outcomes in older individuals [16], [17]. 
Some previous studies have identified 
diagnostic cytogenetic as a key determinant of 
outcome in AML. Recent studies have revealed that 
the disorder arises from a series of recurrent 
hematopoietic stem cell genetic alterations 
accumulated with age [18]. The incidence of 
chromosomal abnormalities in AML differs according 
to geographical regions in the world. In this article, we 
analyse the largest cohort of patients with AML in the 
elderly done in Morocco. This study aims to describe 
the profile of our patients and destining subgroups. 
We defined prognosis subgroup, only 8 patients (6%) 
were in a favorable risk group, the most frequency of 
the common cytogenetic abnormalities detected at 
diagnosis permit to classified patients in the 
intermediate risk group with 94 patients (67%), and 
unfavourable risk group include 38 patients (27%). In 
light of our result, our diagnosis approach has to 
change with including molecular studies in our routine, 
and some of our patients will benefit from intensive 
chemotherapy.  
In our study, some rare abnormalities were 
detected as t(3,5)(q26;q34) as a sole anomaly on 68 
years old patient, this translocation was described on 
two cases, a 48 years old female patient and an 
unknown male age both with M2 AML, we also found 
t(5,16)(q23,q22) on 61 years old man, it’s a rare 
abnormality, only two cases were reported in 
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literature. t(6,12) (q12;p12) was isolated on man 
having 61 years old, it’s very rare abnormality in AML, 
other rare abnormalities were detected as 
t(13,14)(p11;q11), t(13,13)(q10;p10), and trisomy 16 
or trisomy 3 which are very rare in AML [10]. Our 
finding is very important; it can help to define novel 
genes and mutations involved in the leukemic 
process. 
In fact, recent molecular studies including 
next-generation sequencing (NGC) testing of myeloid 
neoplasms (MNs) have shown that acquired 
mutational events that can involve FLT3, NPM1, 
CEBPA, DNMT3A, IDH1, IDH2, KIT, MLL-PTD, TET, 
RUNX1, ASXL1, and TP53 are frequent in the novo 
AML or MDS and can be used for risk stratification, 
especially in patients with normal karyotype [19], [20], 
[21], [22]. 
 In conclusion, the outcome in elderly with 
AML continuously declines with progressively 
increasing age. Comorbid conditions, performance 
status, adverse cytogenetic and unfavourable 
molecular aberrations are among the most critical 
determinant factors. This paper furnishes clinically 
and biological information, this background 
information can be useful in our treatment approach 
especially for the patient from favourable risk group 
who can benefit from intensive chemotherapy. Early 
referral to palliative medicine and the use of this 
subspecialty as a supportive care service it’s not 
always the best proposition for those patients. This 
work sheds light on some missing practice on our 
routine like molecular studies which can offer useful 
guidance during the treatment. 
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